PTD-DBM — protein transduction domain Dvl binding motif
In short
Peptide inhibiting CXXC5-Dishevelled interaction, studied in dermatological models for Wnt signaling modulation.
Overview
PTD-DBM is a synthetic cell-penetrating peptide developed by researchers at Yonsei University. It consists of a protein transduction domain attached to a Dishevelled-binding motif. The peptide is designed to intervene in the Wnt/β-catenin signaling pathway, which regulates hair follicle development and regeneration. Researchers utilize PTD-DBM primarily to study hair neogenesis and the cellular mechanisms underlying androgenetic alopecia.
PTD-DBM functions by competitively binding to the Dishevelled (Dvl) protein inside cells. This action prevents the CXXC5 protein from binding to Dvl, an interaction that normally suppresses the Wnt/β-catenin signaling pathway. By blocking this negative feedback loop, the peptide restores Wnt/β-catenin signaling activity. Elevated Wnt signaling promotes the activation of stem cells in the hair follicle bulge, stimulating new hair growth and follicle regeneration.
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Lee et al. (J Invest Dermatol 2017) - topical application induces hair regrowth with density comparable to sustained minoxidil therapy over 4 weeks.
Дългосрочният профил на безопасност все още не е установен. Използвайте само под медицинско наблюдение. Може да причини локално дразнене, зачервяване или сърбеж на мястото на приложение. Теоретичен риск от свръхстимулиране на Wnt пътищата в нецелеви тъкани при системна абсорбция. Не се препоръчва за лица с анамнеза за злокачествени кожни заболявания. Безопасността по време на бременност и кърмене не е оценена.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Lee
Animal | topical | 4 weeks | Hair regrowth ~ minoxidil
J Invest Dermatol · 2017
View the studyInformation about PTD-DBM is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
